212 related articles for article (PubMed ID: 16913696)
21. Prediction of hERG potassium channel affinity by the CODESSA approach.
Coi A; Massarelli I; Murgia L; Saraceno M; Calderone V; Bianucci AM
Bioorg Med Chem; 2006 May; 14(9):3153-9. PubMed ID: 16426850
[TBL] [Abstract][Full Text] [Related]
22. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
23. Quantitative structure-activity relationship models for predicting biological properties, developed by combining structure- and ligand-based approaches: an application to the human ether-a-go-go-related gene potassium channel inhibition.
Coi A; Massarelli I; Saraceno M; Carli N; Testai L; Calderone V; Bianucci AM
Chem Biol Drug Des; 2009 Oct; 74(4):416-33. PubMed ID: 19751420
[TBL] [Abstract][Full Text] [Related]
24. Topological mapping of the asymmetric drug binding to the human ether-à-go-go-related gene product (HERG) potassium channel by use of tandem dimers.
Myokai T; Ryu S; Shimizu H; Oiki S
Mol Pharmacol; 2008 Jun; 73(6):1643-51. PubMed ID: 18326583
[TBL] [Abstract][Full Text] [Related]
25. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Wiśniowska B; Mendyk A; Fijorek K; Glinka A; Polak S
J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
[TBL] [Abstract][Full Text] [Related]
26. Bias-correction of regression models: a case study on hERG inhibition.
Hansen K; Rathke F; Schroeter T; Rast G; Fox T; Kriegl JM; Mika S
J Chem Inf Model; 2009 Jun; 49(6):1486-96. PubMed ID: 19435326
[TBL] [Abstract][Full Text] [Related]
27. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
[TBL] [Abstract][Full Text] [Related]
28. Toward a consensus model of the HERG potassium channel.
Stary A; Wacker SJ; Boukharta L; Zachariae U; Karimi-Nejad Y; Aqvist J; Vriend G; de Groot BL
ChemMedChem; 2010 Mar; 5(3):455-67. PubMed ID: 20104563
[TBL] [Abstract][Full Text] [Related]
29. Computational investigations of hERG channel blockers: New insights and current predictive models.
Villoutreix BO; Taboureau O
Adv Drug Deliv Rev; 2015 Jun; 86():72-82. PubMed ID: 25770776
[TBL] [Abstract][Full Text] [Related]
30. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
31. ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage.
Wang S; Li Y; Wang J; Chen L; Zhang L; Yu H; Hou T
Mol Pharm; 2012 Apr; 9(4):996-1010. PubMed ID: 22380484
[TBL] [Abstract][Full Text] [Related]
32. Medicinal chemistry of hERG optimizations: Highlights and hang-ups.
Jamieson C; Moir EM; Rankovic Z; Wishart G
J Med Chem; 2006 Aug; 49(17):5029-46. PubMed ID: 16913693
[No Abstract] [Full Text] [Related]
33. In silico prediction of hERG inhibition.
Jing Y; Easter A; Peters D; Kim N; Enyedy IJ
Future Med Chem; 2015; 7(5):571-86. PubMed ID: 25921399
[TBL] [Abstract][Full Text] [Related]
34. Computer simulations of structure-activity relationships for HERG channel blockers.
Boukharta L; Keränen H; Stary-Weinzinger A; Wallin G; de Groot BL; Aqvist J
Biochemistry; 2011 Jul; 50(27):6146-56. PubMed ID: 21657256
[TBL] [Abstract][Full Text] [Related]
35. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels.
Perrin MJ; Kuchel PW; Campbell TJ; Vandenberg JI
Mol Pharmacol; 2008 Nov; 74(5):1443-52. PubMed ID: 18701618
[TBL] [Abstract][Full Text] [Related]
36. Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies.
Masetti M; Cavalli A; Recanatini M
J Comput Chem; 2008 Apr; 29(5):795-808. PubMed ID: 17926340
[TBL] [Abstract][Full Text] [Related]
37. Tuning out of hERG.
Aronov AM
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):128-40. PubMed ID: 18175275
[TBL] [Abstract][Full Text] [Related]
38. Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers.
Thai KM; Ecker GF
Mol Divers; 2009 Aug; 13(3):321-36. PubMed ID: 19219559
[TBL] [Abstract][Full Text] [Related]
39. Predictive in silico modeling for hERG channel blockers.
Aronov AM
Drug Discov Today; 2005 Jan; 10(2):149-55. PubMed ID: 15718164
[TBL] [Abstract][Full Text] [Related]
40. Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.
Karczewski J; Wang J; Kane SA; Kiss L; Koblan KS; Culberson JC; Spencer RH
Biochem Pharmacol; 2009 May; 77(10):1602-11. PubMed ID: 19426697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
